Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Ino7.0
Inositol – Forschung
Hilft vermutlich
188 begutachtete Studien
Was die Evidenz sagt
Hilft wahrscheinlich
Inositol scheint in 14 von 20 Studien mit messbaren Effekten zu helfen — die Evidenz tendiert klar ins Positive.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 1986–2026 mit einer typischen Studiengröße von 464 Teilnehmenden.
Basierend auf 186 Studien · 42 Meta-Analysen · 104 RCTs · 79,551 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
14geholfen3unklar3nicht geholfen· 166 weitere ohne bewertete Effektdaten
Nach Outcome
Women's health
Hilft vermutlich175 Studien
Glucose & metabolicVerbesserte Insulinsensitivität, insbesondere bei PCOS · 4-12 weeks · Verbessert die Insulinsensitivität und metabolische Marker · 8-12 weeks
Hilft vermutlich165 Studien
Fertility & reproductive
Hilft vermutlich37 Studien
Therapeutic & clinical
Überwiegend Mechanismus / Beobachtung26 Studien
Weight managementUnterstützung der Körperzusammensetzung, insbesondere bei PCOS · 4-12 weeks
Hilft wahrscheinlich19 Studien
Anxiety & stressSignifikante Reduktion von Angst- und Paniksymptomen · 4-6 weeks
Men's vitalityStarke Evidenz für die Normalisierung des Hormonhaushalts und die Insulinsensibilisierung bei PCOS · 4-12 weeks
Überwiegend Mechanismus / Beobachtung7 Studien
Skin health
Überwiegend Mechanismus / Beobachtung7 Studien
Safety profile
Hilft wahrscheinlich6 Studien
Heart & blood pressure
Überwiegend Mechanismus / Beobachtung3 Studien
Cholesterol & lipids
Zu wenige bewertete Studien2 Studien
Cognitive function
Zu wenige bewertete Studien2 Studien
In Zahlen
Aus 52 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
89%
über Studien hinweg
Untersuchte Personen
80k
typische Studie: 464 Personen
Stärkste Designs
146
42 gepoolt, 104 randomisiert
Zeigte Nutzen
70%
14/20 Studien
Wie lange Studien liefen
1–3 Monate
4
Untersuchte Populationen
Women with PCOS8
Pregnant women5
Women with polycystic ovary syndrome3
overweight pregnant women2
Aktives Forschungsgebiet
77 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2026
198620062026
1PCOS symptoms improvementMeta-Analysen=5,501 · very large study2025
Einfach gesagt: Chromium, inositol, and Omega-3 were found to be beneficial for improving lipid profile.
Zhao G et al. · Reproductive biology and endocrinology : RB&E (2025)
Inositol significantly decreased total cholesterol and triglyceride levels, while curcumin was most effective in improving low-density and high-density lipoprotein cholesterol levels.
Chromium, inositol, and Omega-3 were found to be beneficial for improving lipid profile.
For improving obesity, sex hormone levels, inflammatory factors and oxidative stress indicators of PCOS patients, carnitine, chromium, and soy isoflavones are effective options, respectively.
2Gestational diabetes preventionMeta-Analysen=1,319 · large study2023
Einfach gesagt: Evidence from seven studies shows that antenatal dietary supplementation with myo-inositol during pregnancy may reduce the incidence of gestational diabetes, hypertensive disorders of pregnancy and preterm birth.
Motuhifonua SK et al. · The Cochrane database of systematic reviews (2023)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
For the primary neonatal outcomes, only one study measured the risk of a large-for-gestational-age infant and found myo-inositol was associated with both appreciable benefit and harm (RR 1.40, 95% CI 0.65 to 3.02; 1 study, 234 infants; low-certainty evidence).
Further, myo-inositol may result in little to no difference in caesarean section (RR 0.91, 95% CI 0.77 to 1.07; 4 studies, 829 women; low-certainty evidence).
For the secondary neonatal outcomes, meta-analysis showed no neonatal hypoglycaemia (RR 3.07, 95% CI 0.90 to 10.52; 4 studies; 671 infants; very low-certainty evidence).
3Body weight and BMI reductionMeta-Analysen=2,362 · very large study2023
Einfach gesagt: Carnitine was relatively effective in reducing body mass, while chromium, Omega-3, and selenium were beneficial for improving glucose metabolism.
Hu X et al. · PeerJ (2023)
The network meta-analysis showed that carnitine, inositol, and probiotics reduced body weight and body mass index (BMI) compared to placebo, and carnitine outperformed the other supplements (SUCRAs: 96.04%, 97.73%, respectively).
Omega-3 lowered fasting blood glucose (FBG) (SUCRAs: 93.53%), and chromium reduced fasting insulin (FINS) (SUCRAs: 72.90%); both were superior to placebo in improving insulin resistance index (HOMA-IR), and chromium was more effective than Omega-3 (SUCRAs: 79.99%).
Selenium was potent in raising the quantitative insulin sensitivity index (QUICKI) (SUCRAs: 87.92%).
4Clinical pregnancy ratesMeta-Analysen=2,617 · very large study2024
Einfach gesagt: The results showed that use of antioxidants not only significantly increased the number of retrieved oocytes and high-quality embryo rates but also reduced the dose of gonadotropin, contributing to...
Shang Y et al. · Advances in nutrition (Bethesda, Md.) (2024)
The results showed that use of antioxidants not only significantly increased the number of retrieved oocytes and high-quality embryo rates but also reduced the dose of gonadotropin, contributing to higher clinical pregnancy rates.
Appropriate antioxidant treatment should be offered at a low dose according to the patient's age and ovarian reserve.
5IVF/ICSI outcomes and OHSS reductionMeta-Analysen=1,827 · large study2024
Einfach gesagt: Metformin and myoinositol may reduce OHSS risk in PCOS patients but did not significantly improve pregnancy outcomes.
Lin L et al. · Journal of ovarian research (2024)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
Myoinositol was linked to a shorter gonadotropin duration (SMD = -1.21, 95% CI -2.03 to -0.38) and fewer side effects (OR = 0.23, 95% CI 0.06-0.83) compared to controls.
Metformin led to lower E2 levels, a higher number of mature oocytes, and increased side effects (SMD = -376.52, 95% CI -610.83 to -142.22; SMD = 2.23, 95% CI 0.36-4.10; OR = 6.85, 95% CI 4.32-10.86) than controls.
Metformin and myoinositol may reduce OHSS risk in PCOS patients but did not significantly improve pregnancy outcomes.
6Regular menstrual cycle in PCOSMeta-Analysen=1,691 · large study2023
Einfach gesagt: Inositol is an effective and safe treatment in PCOS.
Greff D et al. · Reproductive biology and endocrinology : RB&E (2023)
Sehr groß Schaden
← SchlechterKein EffektBesser →
In patients treated with inositols, the risk (CI: 1.13; 2.85) of having a regular menstrual cycle was found by 1.79 higher than in the case of placebo.
7Menstrual frequency improvementMeta-Analysen=1,079 · large study2021
Einfach gesagt: Ours is the first study to report that for women with PCOS, myo-inositol combined with D-chiro-inositol and metformin combined with thiazolidinediones appear superior to metformin alone in improving insulin resistance and decreasing total testosterone.
Zhao H et al. · Reproductive health (2021)
Sehr groß Schaden
← SchlechterKein EffektBesser →
Compared with metformin, treatment with myo-inositol + D-chiro-inositol was associated with a greater improvement in menstrual frequency (odds ratio 14.70 [95% confidence interval (CI) 2.31-93.58]).
Ours is the first study to report that for women with PCOS, myo-inositol combined with D-chiro-inositol and metformin combined with thiazolidinediones appear superior to metformin alone in improving insulin resistance and decreasing total testosterone.
Myo-inositol combined with D-chiro-inositol is particularly efficacious in menstrual recovery.
8Cycle regularization in PCOSMeta-Analysen=388 · medium study2025
Einfach gesagt: In this meta-analysis of RCTs, combination therapy was associated with cycle regularization and reduction in hirsutism and LH/FSH ratio compared to metformin monotherapy.
Kelly FA et al. · Endocrine (2025)
Differences in acne (p = 0.58), body mass index (p = 0.13), fasting blood glucose (p = 0.07) and HOMA-IR (p = 0.25) were not statistically significant.
In this meta-analysis of RCTs, combination therapy was associated with cycle regularization and reduction in hirsutism and LH/FSH ratio compared to metformin monotherapy.
Further studies are needed to clarify the true benefits of the use of inositol in PCOS treatment.
9Live birth ratesMeta-Analysen=4,451 · very large study2017
Einfach gesagt: Our updated review suggests that metformin alone may be beneficial over placebo for live birth, although the evidence quality was low.
Morley LC et al. · The Cochrane database of systematic reviews (2017)
Kein klarer Effekt
← SchlechterKein EffektBesser →
Metformin versus placebo or no treatmentThe evidence suggests that metformin may improve live birth rates compared with placebo (OR 1.59, 95% CI 1.00 to 2.51, 4 studies, 435 women, I2 = 0%, low-quality evidence).
There was no clear evidence of a difference in miscarriage rates (OR 1.08, 95% CI 0.50 to 2.35, 4 studies, 748 women, I2 = 0%, low-quality evidence).
However, the combined therapy group had higher rates of clinical pregnancy (OR 1.59, 95% CI 1.27 to 1.99, 16 studies, 1529 women, I2 = 33%, moderate-quality evidence) and ovulation (OR 1.57, 95% CI 1.28 to 1.92, 21 studies, 1624 women, I2 = 64%, moderate-quality evidence).
10Live birth rateMeta-Analysen=7,760 · very large study2020
Einfach gesagt: In this review, there was low- to very low-quality evidence to show that taking an antioxidant may benefit subfertile women.
Showell MG et al. · The Cochrane database of systematic reviews (2020)
Sehr groß Schaden
← SchlechterKein EffektBesser →
Likely real
Due to the very low-quality of the evidence we are uncertain whether antioxidants improve live birth rate compared with placebo or no treatment/standard treatment (odds ratio (OR) 1.81, 95% confidence interval (CI) 1.36 to 2.43; P < 0.001, I2 = 29%; 13 RCTs, 1227 women).
This suggests that among subfertile women with an expected live birth rate of 19%, the rate among women using antioxidants would be between 24% and 36%.
Low-quality evidence suggests that antioxidants may improve clinical pregnancy rate compared with placebo or no treatment/standard treatment (OR 1.65, 95% CI 1.43 to 1.89; P < 0.001, I2 = 63%; 35 RCTs, 5165 women).
17Hormonal and metabolic parameters in PCOSMeta-Analysen=460 · medium study2023
Einfach gesagt: Our meta-analysis comparing hormonal and metabolic parameters between MET and MI did not show much significant difference, indicating both drugs are equally beneficial in improving metabolic and hormonal parameters in patients with PCOS.
Fatima K et al. · Irish journal of medical science (2023)
Our meta-analysis comparing hormonal and metabolic parameters between MET and MI did not show much significant difference, indicating both drugs are equally beneficial in improving metabolic and hormonal parameters in patients with PCOS.
20Treatment response in trichotillomaniaMeta-Analysen=286 · medium study2021
Einfach gesagt: There was insufficient evidence from meta-analysis to confirm or refute the efficacy of any agent or class of medication for the treatment of TTM in adults, children or adolescents.
Hoffman J et al. · The Cochrane database of systematic reviews (2021)
Kein klarer Effekt
← SchlechterKein EffektBesser →
Antioxidants versus placebo in adolescents There was little to no difference in treatment response between antioxidant (50%) and placebo groups (25%) after six weeks, based on a single trial of silymarin (RR 2.00, 95% CI 0.28 to 14.20; 8 participants; low-certainty evidence).
Antipsychotics versus placebo in adults There may be greater treatment response in the antipsychotic group (85%) compared to the placebo group (17%) after 12 weeks, based on a single trial of olanzapine (RR 5.08, 95% CI 1.4 to 18.37; 25 participants; low-certainty evidence).
Cell signal transducers versus placebo in adults There was little to no difference in treatment response between cell signal transducer (42.1%) and placebo groups (31.6%) after 10 weeks, based on a single trial of inositol (RR 1.33, 95% CI 0.57 to 3.11; 38 participants; low-certainty evidence).